Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27161642 | 0.90 | CYP2D6 (0.52) | CHRM2CHRM3NR1H2ALDH1A1 | |
| SCHEMBL403480 | 0.88 | SIGMAR1 (0.53) | CHRM2CHRM4CHRM1CHRM3NR1H2 | |
| SCHEMBL24732680 | 0.88 | PRMT6 (0.54) | GLSMGLLCHRM2CHRM4CHRM1 | |
| SCHEMBL8540779 | 0.86 | ALDH1A1 (0.63) | GLSCHRM2CHRM3ALDH1A1HTT | |
| SCHEMBL4837787 | 0.86 | GLS (0.54) | GLSMGLLCHRM2CHRM4CHRM1 | |
| SCHEMBL13236926 | 0.86 | GLS (0.54) | GLSMGLLCHRM2CHRM4CHRM1 | |
| SCHEMBL2194827 | 0.86 | KDM1A (0.57) | GLSMGLLCHRM2CHRM4CHRM1 | |
| SCHEMBL7852144 | 0.86 | FAAH (0.51) | MGLLALDH1A1HTTKDM4E | |
| SCHEMBL4709921 | 0.85 | GLS (0.52) | GLSMGLLCHRM2CHRM4CHRM1 | |
| SCHEMBL14987039 | 0.85 | GLS (0.56) | GLSMGLLCHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| CN-117285485-A | Bis-sulfonamide derivative and preparation method and application thereof | 复旦大学 | 2023-12-26 | — | — | CN | disclosed |
| EP-4259145-A1 | ALK-5 INHIBITORS AND USES THEREOF | Sumitomo Pharma Oncology, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116546986-A | ALK-5 inhibitors and uses thereof | 住友制药肿瘤公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2022126133-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY,INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20210246122-A1 | Triazine Compounds and Uses Thereof | Aduro Biotech, Inc. (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210246122-A1 | Triazine Compounds and Uses Thereof | Aduro Biotech, Inc. (US) | 2021-08-12 | — | — | US | disclosed |
| US-7285664-B2 | Heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | S.C.R.A.S. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| US-20050227991-A1 | New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-13 | — | — | US | disclosed |
| US-6936715-B2 | Lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2005-08-30 | — | — | US | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
| US-20030105107-A1 | Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | IPSEN PHARMA S.A.S. (FR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | GLS 1164/4885MGLL 3774/4885CHRM2 206/4885 |
| US-20030105107-A1 | Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | LTC4S, LPO, COASY | GLS 316/4885MGLL 2173/4885CHRM2 2014/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | GLS 2921/4885MGLL 3531/4885CHRM2 4814/4885 |
| US-20050227991-A1 | New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | LPO, LTC4S, BBOX1 | GLS 228/4885MGLL 1557/4885CHRM2 1998/4885 |
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | ACVR1, ALK, ACVRL1 | GLS 1329/4885MGLL 3012/4885CHRM2 1879/4885 |
| US-20210246122-A1 | Triazine Compounds and Uses Thereof | IL5, IL15, TLR5 | GLS 1089/4885MGLL 2855/4885CHRM2 1266/4885 |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | ACVR1, ALK, ACVRL1 | GLS 1329/4885MGLL 3012/4885CHRM2 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.